
News|Articles|October 1, 2006
Pipeline Preview (October 2006)
Dalteparin (Fragmin, Pfizer) for the extended treatment of symptomatic venous thromboembolism (proximal deep vein thrombosis and/or pulmonary embolus) to prevent recurrent venous thromboembolism in patients with cancer
Advertisement
Recommendations for approval
Recommendations against approval
Nonapprovable designations
Newsletter
Get the latest industry news, event updates, and more from Managed healthcare Executive.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
Advancing Equity and Access in Breast Cancer Care
2
Type 1 Diabetes Drug Tzield Under Expedited Review Through New FDA Program
3
Final Takeaways of the GALAXI-2 and GALAXI-3 Trials From Lead Investigators
4
Aflibercept 8 mg Shows Promise in Reducing Injection Burden | AAO 2025
5